Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in LeMaitre Vascular, Inc. or Insulet Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how LeMaitre Vascular, Inc. and Insulet Corporation compare based on key financial metrics to determine which better meets your investment needs.

About LeMaitre Vascular, Inc. and Insulet Corporation

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Latest Health Care Equipment & Supplies and LeMaitre Vascular, Inc., Insulet Corporation Stock News

As of July 30, 2026, LeMaitre Vascular, Inc. had a $2.3 billion market capitalization, compared to the Health Care Equipment & Supplies median of $334.8 million. LeMaitre Vascular, Inc.’s stock is up 24.9% in 2026, up 6% in the previous five trading days and up 23.98% in the past year.

Currently, LeMaitre Vascular, Inc.’s price-earnings ratio is 37.6. LeMaitre Vascular, Inc.’s trailing 12-month revenue is $256.3 million with a 24.3% net profit margin. Year-over-year quarterly sales growth most recently was 11.2%. Analysts expect adjusted earnings to reach $3.000 per share for the current fiscal year. LeMaitre Vascular, Inc. currently has a 1.0% dividend yield.

As of July 30, 2026, Insulet Corporation had a $11.5 billion market cap, putting it in the 79th percentile of all stocks. Insulet Corporation’s stock is down 41.8% in 2026, up 1.3% in the previous five trading days and down 43.15% in the past year.

Currently, Insulet Corporation’s price-earnings ratio is 38.6. Insulet Corporation’s trailing 12-month revenue is $2.9 billion with a 10.4% net profit margin. Year-over-year quarterly sales growth most recently was 33.9%. Analysts expect adjusted earnings to reach $6.482 per share for the current fiscal year. Insulet Corporation does not currently pay a dividend.

How We Compare LeMaitre Vascular, Inc. and Insulet Corporation Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at LeMaitre Vascular, Inc. and Insulet Corporation’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

LeMaitre Vascular, Inc. and Insulet Corporation Stock Value Grades

Company	Ticker	Value
LeMaitre Vascular, Inc.	LMAT	F
Insulet Corporation	PODD	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

LeMaitre Vascular, Inc. has a Value Score of 12, which is Ultra Expensive. Insulet Corporation has a Value Score of 17, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither LeMaitre Vascular, Inc. or Insulet Corporation has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if LeMaitre Vascular, Inc. or Insulet Corporation is the better investment when it comes to value.

LeMaitre Vascular, Inc. and Insulet Corporation Growth Grades

Company	Ticker	Growth
LeMaitre Vascular, Inc.	LMAT	A
Insulet Corporation	PODD	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

LeMaitre Vascular, Inc. has a Growth Score of 89, which is Very Strong. Insulet Corporation has a Growth Score of 40, which is Weak.

The Growth Grade Winner: LeMaitre Vascular, Inc.

As you can clearly see from the Growth Grade breakdown above, LeMaitre Vascular, Inc. has a more attractive growth grade than Insulet Corporation. For investors who focus solely on how a company is growing relative to other companies in the same industry, LeMaitre Vascular, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

LeMaitre Vascular, Inc. and Insulet Corporation’s Momentum Grades

Company	Ticker	Momentum
LeMaitre Vascular, Inc.	LMAT	C
Insulet Corporation	PODD	F

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

LeMaitre Vascular, Inc. has a Momentum Score of 52, which is Average. Insulet Corporation has a Momentum Score of 18, which is Very Weak.

The Momentum Stock Winner: No Clear Winner

Neither LeMaitre Vascular, Inc. or Insulet Corporation has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if LeMaitre Vascular, Inc. or Insulet Corporation is the better investment when it comes to momentum.

Other LeMaitre Vascular, Inc. and Insulet Corporation Grades

In addition to Value, Growth and Momentum, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether LeMaitre Vascular, Inc. and Insulet Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, LeMaitre Vascular, Inc. or Insulet Corporation Stock?

Overall, LeMaitre Vascular, Inc. stock has a Value Score of 12, Growth Score of 89 and Momentum Score of 52.

Insulet Corporation stock has a Value Score of 17, Growth Score of 40 and Momentum Score of 18.

Comparing LeMaitre Vascular, Inc. and Insulet Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.